Australia Moves Closer To Reducing HTA Discount Rate For First Time In Decades
Executive Summary
The pharmaceutical industry body Medicines Australia has welcomed an advisory committee’s recommendation on reducing the 5% discount rate that has been used in health technology assessments for 30 years, although it would have liked to see a bigger reduction and to have it implemented more quickly.
You may also be interested in...
Australian HTA Consults On Discount Rate
PBAC, Australia’s health technology assessment body, is asking for feedback on whether its discount rate – a tool used in economic modelling – is too high.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.